Loading…
← CockpitCompetitor Analysis › APLLTD.NS Alembic Pharmaceuticals LimitedOpen in the cockpit ↗

Alembic Pharmaceuticals LimitedAPLLTD.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Manufactures generic APIs and formulations, exporting to the US and other regulated markets alongside domestic branded generics.

≈ A mid-sized Indian generics/API exporterMomentum leader 94
Mkt cap
$2.20B
US dollars, full cap
Free float
30%
of shares outstanding
$/day
$6.46M
20-day average traded
Fwd P/E
25.0×
forward earnings
ROIC−WACC
-3.1 pp
WACC 14.0%
Hurdle
+20 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · INR₹1,044
1D-0.6%
1W+1.4%
1M+32.1%
3M+26.7%
6M+39.0%
YTD+23.4%
1Y+13.9%
ATR %3.5%
Beta0.94
52w lowhigh2.9% off high

What Alembic Pharmaceuticals does

Manufactures generic APIs and formulations, exporting to the US and other regulated markets alongside domestic branded generics.

Sells generics in the US through wholesalers and pharmacy chains, where new approvals and price pressure on older products decide the direction, alongside branded drugs sold to Indian doctors and active ingredients sold to other drugmakers. It was demerged from Alembic Limited in 2010, and the Amin family still leads it.

In one line: A mid-sized Indian generics/API exporter.

Products and services

  • US generic formulations
  • Domestic branded generics
  • APIs
  • Oncology/respiratory products

Customers

  • US pharmacy distributors
  • Indian doctors/pharmacies

Where it sits in the supply chain

  • API manufacturing
  • Formulation manufacturing
  • Domestic branded generics + US export

What could go right

  • US generic launches
  • Domestic branded growth

What could go wrong

  • US generic price erosion
  • FDA inspection/compliance risk

Moat: narrow (regulatory licence, brand). US FDA-approved plants plus a century-old domestic brand support a dual regulated/branded business.

Headquarters: Vadodara, India · Founded: 1907 · Employees: 20,149

Named competitors

Alembic Pharmaceuticals at a glance

Size Alembic Pharmaceuticals (APLLTD.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $2.20B, the 359th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,044 on 18 Nov 2026.

Performance Over six months the shares gained 39.0%, against -4.9% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 19.7% over the last twelve months (peer median +4.7%); the operating margin is 12.4% (peer median 11.8%).

Valuation It trades at 25.0× forward earnings against a peer median of 17.5× (7th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.1 points below its cost of capital (14.0% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026APLLTD.NS 139Peer median 97
Six months, rebased to 100: Alembic Pharmaceuticals against the median of its 20 peers (local-currency closes).

Alembic Pharmaceuticals financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹84.8B₹72.2B₹65.5B₹61.2B₹55.7B
Revenue growth—+10%+7%+10%—
Gross profit₹38.9B₹25.6B₹23.2B₹21.6B₹19.0B
EBITDA₹14.2B₹10.1B₹9.04B₹8.48B₹6.64B
Net income₹8.44B₹6.75B₹5.83B₹6.16B₹3.42B
Free cash flown/a₹2.61B-₹5.49B₹4.30B₹2.32B
Capital expendituren/a₹4.95B₹5.64B₹3.27B₹4.43B
Total debt₹15.5B₹14.3B₹12.6B₹5.13B₹7.22B

Quarterly statements and history in the cockpit →

Alembic Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%600867600267603858214450301080H02RGC688428PRGO000250600285NAMS603707001360345630043621623696009420APLLTD.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Alembic Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%25×50×75×600867600267214450301080H02688428PRGO60028560370700133696PBHAPLLTD.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alembic Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%600867600267214450301080688428PRGO0013APLLTD.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Alembic Pharmaceuticals is the large dot.

Alembic Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (APLLTD.NS vs AUROPHARMA.NS vs LUPIN.NS vs CIPLA.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Alembic Pharmaceuticals APLLTD.NS$2.20B+39%+20%12%25.0×26.7%
Aurobindo Pharma AUROPHARMA.NS$11.0B+19%+14%15%22.3×21.1%
Lupin LUPIN.NS$9.67B-14%+24%24%21.0×8.8%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%

How Alembic Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alembic Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureAPLLTD.NSPeer medianRank in peer set
1-month return+32.1%-5.5%highest of 21
6-month return+39.0%-4.9%3rd highest of 21
Distance from 52-week high-2.9%-29.6%3rd highest of 21
Revenue growth (TTM)+19.7%+4.7%6th highest of 20
Operating margin12.4%11.8%10th highest of 19
Forward P/E25.0×17.5×7th most expensive of 15
Growth the price implies (Req g, 7 yrs)26.7%2.0%4th most demanding of 15
Growth delivered (Del g)+6.5%+13.1%7th lowest of 15
Hurdle (Req g minus delivered)+20.2 pp-0.9 pp2nd most demanding of 15
ROIC minus cost of capital-3.1 pp-0.4 pp7th lowest of 16
EV / EBITDA15.4×11.8×2nd most expensive of 5
Net debt / EBITDA0.9×0.5×4th least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%55.2×41.3%+27.7%
Haw Par H02.SISingapore$2.08B-25%-13%30%11.9×3.2%+15.7%
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
InnoCare Pharma 688428.SSChina$2.07B-7%+135%35%85.7×-10.9%+344.2%
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a

Questions

Who are Alembic Pharmaceuticals's main competitors?
Named competitors: Aurobindo Pharma (AUROPHARMA.NS), Lupin (LUPIN.NS), Cipla (CIPLA.NS). The cockpit's measured peer set (industry) also includes Tonghua Dongbao Pharmaceutical (600867.SS), Zhejiang Hisun Pharmaceutical (600267.SS), Shandong Buchang Pharmaceuticals (603858.SS), PharmaResearch (214450.KS), Acrobiosystems (301080.SZ), Haw Par (H02.SI).
Is Alembic Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 25.0× against a peer median of 17.5×, 7th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Alembic Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +39.0% against -4.9% for the median peer; over one year +13.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.